179 related articles for article (PubMed ID: 36640753)
41. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
Moslehi J; Lichtman AH; Sharpe AH; Galluzzi L; Kitsis RN
J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33645548
[TBL] [Abstract][Full Text] [Related]
42.
Boughdad S; Latifyan S; Fenwick C; Bouchaab H; Suffiotti M; Moslehi JJ; Salem JE; Schaefer N; Nicod-Lalonde M; Costes J; Perreau M; Michielin O; Peters S; Prior JO; Obeid M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34686542
[TBL] [Abstract][Full Text] [Related]
43. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.
Makunts T; Saunders IM; Cohen IV; Li M; Moumedjian T; Issa MA; Burkhart K; Lee P; Patel SP; Abagyan R
Sci Rep; 2021 Aug; 11(1):17324. PubMed ID: 34462476
[TBL] [Abstract][Full Text] [Related]
44. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review.
Cozma A; Sporis ND; Lazar AL; Buruiana A; Ganea AM; Malinescu TV; Berechet BM; Fodor A; Sitar-Taut AV; Vlad VC; Negrean V; Orasan OH
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142866
[TBL] [Abstract][Full Text] [Related]
45. Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.
Bockstahler M; Fischer A; Goetzke CC; Neumaier HL; Sauter M; Kespohl M; Müller AM; Meckes C; Salbach C; Schenk M; Heuser A; Landmesser U; Weiner J; Meder B; Lehmann L; Kratzer A; Klingel K; Katus HA; Kaya Z; Beling A
Circulation; 2020 Jun; 141(23):1885-1902. PubMed ID: 32160764
[TBL] [Abstract][Full Text] [Related]
46. Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries.
Hu X; Wei Y; Shuai X
Front Immunol; 2021; 12():799077. PubMed ID: 34975911
[TBL] [Abstract][Full Text] [Related]
47. Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies.
Turker I; Johnson DB
Expert Opin Drug Saf; 2023; 22(10):909-919. PubMed ID: 37647330
[TBL] [Abstract][Full Text] [Related]
48. Acute Myocarditis After Discontinuation of Immune Checkpoint Inhibitor Therapy.
Tamura Y; Tamura Y; Taniguchi H; Imanaka-Yoshida K
Circ J; 2023 Jan; 87(2):376. PubMed ID: 36310041
[No Abstract] [Full Text] [Related]
49. [A case report of immune checkpoint inhibitor-induced myocarditis].
Liao HL; Chen DD; Pan Y; Liu ZJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):710-712. PubMed ID: 35856230
[TBL] [Abstract][Full Text] [Related]
50. Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Naqash AR; Moey MYY; Cherie Tan XW; Laharwal M; Hill V; Moka N; Finnigan S; Murray J; Johnson DB; Moslehi JJ; Sharon E
J Clin Oncol; 2022 Oct; 40(29):3439-3452. PubMed ID: 35658474
[TBL] [Abstract][Full Text] [Related]
51. Fatal myocarditis after the first dose of nivolumab.
Zomborska E; Kasperova S; Slopovsky J; Pazderová N; Kasperova B; Penz P; Nyitrayová O; Salek T; Porsok S; Mladosievicova B; Mego M
Klin Onkol; 2022; 35(6):486-492. PubMed ID: 36513516
[TBL] [Abstract][Full Text] [Related]
52. Immune Checkpoint Inhibitor Toxicity in 2018.
Johnson DB; Chandra S; Sosman JA
JAMA; 2018 Oct; 320(16):1702-1703. PubMed ID: 30286224
[No Abstract] [Full Text] [Related]
53. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
54. Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/-associated antibodies.
Isa M; Hongo Y; Sakamoto N; Yamazaki K; Takazaki H; Asakuma J; Ikewaki K; Suzuki K
J Neurol Sci; 2023 Jan; 444():120528. PubMed ID: 36565689
[No Abstract] [Full Text] [Related]
55. Immune Checkpoint Inhibitor Rechallenge in a Patient With Previous Fulminant Myocarditis.
Menachery SM; Hang Y; Pritchard L; Poklepovic A; Bottinor W
Am J Cardiol; 2023 Jul; 199():33-36. PubMed ID: 37245247
[No Abstract] [Full Text] [Related]
56. Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report.
Ye Y; Li Y; Zhang S; Han G
J Int Med Res; 2022 Oct; 50(10):3000605221133259. PubMed ID: 36300305
[TBL] [Abstract][Full Text] [Related]
57. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
[No Abstract] [Full Text] [Related]
58. Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration.
Liu Z; Fan Y; Guo J; Bian N; Chen D
ESC Heart Fail; 2022 Jun; 9(3):2020-2026. PubMed ID: 35322589
[TBL] [Abstract][Full Text] [Related]
59. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
60. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
